SBM.V Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 24, 2025
Report Source: 2024 3rd Quarter Report
Sirona Biochem Corp. Stock Analysis SBM.V
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform technology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2007-07-10. The company specializes in stabilizing carbohydrate molecules. The company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two advanced programs are the cosmetic skin lightener and diabetes drug. Other projects include the development of an anti-aging / cell protection library, a novel anti-wrinkle compound, and the launch of an anti-viral program. Its TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. The company is focused on three antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its subsidiary is TFChem S.A.R.L.
Read More Sirona Biochem Corp (SBM.V) Chart
Key Statistics of Sirona Biochem Corp (SBM.V)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD0.06Volume
182.01KP/E Ratio (TTM)
-52 Week Range
Market Cap
15.77MAvg. Volume
102.03KDividend Yield
-Financial Metrics & Statements of Sirona Biochem Corp (SBM.V)
FAQ's for Sirona Biochem Corp (SBM.V)
- According to Musaffa’s Shariah screening methodology, Sirona Biochem Corp (SBM.V) is currently classified as NOT HALAL as of March 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.